A systematic review published in JAMA Psychiatry looks at weight loss drugs (GLP-1 receptor agonists) and mental health. Prof Stella Chan, Charlie Waller Chair in Evidence-based Psychological ...

Point32Health will dramatically change how and when it pays for Zepbound — the insurer’s preferred GLP-1 weight-loss drug— ...

The Ozempic maker and its peers are setting their sights on oral obesity medications to diversify their portfolios and remain ...

On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...

Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated ...

We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

From my colleague Jason Mast: The first ever patient has been treated with prime editing, a powerful technology for making ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Septerna (SEPN) for obesity pills — the ...

According to a recent study, glucagon-like peptide-1 receptor agonists are associated with a reduction in alcohol intake.

GLP1 drugs are changing patients eating and grocery shopping habits - 2 News Oklahoma's Cathy Tatom hears how from a patient, ...

Shares of Septerna Inc. were soaring in early Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...